AAN Annual Meeting 2027
The AAN Annual Meeting 2027 will take place May 1–5, 2027, in Washington, DC, and online. The American Academy of Neurology’s upcoming conference schedule 🔗 confirms the dates, city, and online option. A specific venue, abstract deadline, registration schedule, scientific program, and exhibitor list had not been published in the official AAN sources reviewed on July 30, 2026.
AAN 2027 Quick Answers
Section titled “AAN 2027 Quick Answers”| Question | Current answer |
|---|---|
| What are the AAN 2027 dates? | May 1–5, 2027 |
| Where is AAN 2027? | Washington, DC, United States; the specific venue has not been announced |
| Is there an online option? | Yes. AAN lists the meeting as taking place in Washington, DC, and online |
| What is the abstract deadline? | Not yet announced for the 2027 Annual Meeting |
| Is registration open? | Not confirmed. No 2027 registration schedule was available in the official sources reviewed |
| Has the scientific program been released? | No 2027 program or session list was available in the official sources reviewed |
| When was this information checked? | July 30, 2026 |
The AAN Annual Meeting is a broad neurology congress rather than a botulinum toxin-specific meeting. Its value for toxin-focused participants will depend on the eventual education program, scientific abstracts, plenary content, and industry sessions. No specific 2027 topic or session should be assumed from earlier editions.
Location And Venue
Section titled “Location And Venue”Washington, DC, is the confirmed host city. AAN’s published future-meeting schedule did not identify a convention center, hotel, street address, or other specific venue as of July 30, 2026.
Open Washington, DC, in Google Maps 🔗. The map points to the host city, not an AAN 2027 venue, and should not yet be used for accommodation or local transportation decisions.
Abstract Deadline
Section titled “Abstract Deadline”The AAN 2027 abstract submission window and deadline have not been announced. Dates from the 2026 Annual Meeting or other AAN conferences should not be treated as the 2027 deadline.
The official AAN Annual Meeting page 🔗 is the controlling source for the eventual submission schedule, eligibility rules, abstract categories, and submission portal.
Registration And Online Format
Section titled “Registration And Online Format”AAN confirms that the 2027 meeting will include both Washington, DC, and online participation. Registration opening dates, rates, access periods, and the exact division between in-person and online content were not yet available for 2027.
Registration decisions should rely on the 2027 information published by AAN rather than the concluded 2026 registration page. The AAN conferences and community section 🔗 provides the organizer’s broader conference navigation.
Botulinum Toxin Program Context
Section titled “Botulinum Toxin Program Context”No session-level 2027 program was available on the official meeting pages reviewed on July 30, 2026. AAN’s upcoming-conferences page confirms only the 2027 dates, location, and online format. When the 2027 program is released, the most relevant search paths are likely to include botulinum toxin terminology alongside movement disorders, dystonia, spasticity, headache, and chronic migraine, but inclusion in the final program remains unconfirmed.
Botulinum toxin may appear within broader neurologic subject areas rather than under a single toxin heading. Relevant program searches may include cervical dystonia, limb spasticity, chronic migraine, hemifacial spasm, and blepharospasm. These are useful search paths once the program is available, not confirmation that any condition or toxin product will appear in 2027.
Program records should distinguish:
- scientific abstracts and investigator-led presentations
- continuing education sessions
- plenary or named lectures
Industry Therapeutic Updatesor other industry-supported programming- exhibit-floor participation
These categories should not be combined into a single evidence class.
Planning Timeline
Section titled “Planning Timeline”| Item | Current status | What to watch for |
|---|---|---|
| Dates and host city | Confirmed | May 1–5, 2027, in Washington, DC |
| Venue and address | Pending | Convention center or other named venue |
| Abstract submission | Pending | Opening date, deadline, categories, and rules |
| Registration | Pending | Opening date, rates, and access options |
| Scientific program | Pending | Searchable sessions, faculty, and education tracks |
| Toxin-specific itinerary | Pending | Abstracts, sessions, and industry programming |
Participating Companies
Section titled “Participating Companies”No 2027 exhibitor, sponsor, or industry-session company list was available in the official sources reviewed. Companies should be added only after AAN identifies their participation and should be classified by role: exhibitor, industry-session sponsor, meeting sponsor, speaker affiliation, or abstract-author affiliation.
Company presence at a neurology meeting does not establish that a specific toxin brand is displayed, discussed, approved, or available in the United States.
Meeting content can identify active research and education topics, but product indications, dosing, safety, and regulatory status still depend on current prescribing information and regulatory sources.